Zai Lab Limited - American Depositary Shares (ZLAB) analyst actions
Rating and price-target actions on ZLAB in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ZLAB overview →
2 measured ZLAB analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Zai Lab Announces Updated Phase 1 Data for Zocilurtatug Pelitecan (formerly ZL-1310), Demonstrating Potential as a First-in-Class/Best-in-Class DLL3-Targeted ADC for Small Cell Lung Cancer, and Initiation of Global Phase 3 Registrational Study | Press release | +0.65% | -5.56% | |
| Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis | Press release | +1.41% | +1.56% |
Keep exploring
More ZLAB: earnings → · SEC filings → · ZLAB overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| BIOPHARMX CORP (BPMX) | 416 | -1.58% | 28% |
| VITAL THERAPIES (VTL) | 415 | -0.05% | 44% |
| Bausch Health Companies Inc. (BHC) | 412 | +0.06% | 50% |
| Verastem, Inc. (VSTM) | 411 | -0.09% | 48% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.